- In May 2023, Hyderabad-based MSN Labs has introduced Fesobig, the world's first bioequivalent generic version of Fesoterodine Fumarate. This medication is endorsed as the safest and most innovative first-line pharmacotherapy option by numerous international treatment guidelines for managing overactive bladder (OAB) and urinary incontinence (UI)
Frequently Asked Questions
The market is segmented based on Segmentation, By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2032
.
The Global Urinary Retention Drugs Market size was valued at USD 3.64 USD Billion in 2024.
The Global Urinary Retention Drugs Market is projected to grow at a CAGR of 7.75% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
